Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

In vitro evaluation of anti-fungal activity of tropicamide against strains of Candida spp. resistant to fluconazole in planktonic and biofilm form

2020; Elsevier BV; Volume: 31; Issue: 1 Linguagem: Inglês

10.1016/j.mycmed.2020.101080

1773-0449

Caio Bezerra Machado, Cecília Rocha da Silva, Fátima Daiana Dias Barroso, Rosana de Sousa Campos, Lívia Gurgel do Amaral Valente Sá, Francisca Bruna Stefany Aires do Nascimento, Bruno C. Cavalcanti, Hélio Vitoriano Nobre Júnior, João Batista de Andrade Neto,

Antibiotic Use and Resistance

Candida spp. is considered to be the third or fourth most common cause of bloodstream infections associated with healthcare services in the world. Currently, several strains exhibit resistance to the traditional treatments, making the development of new therapeutic molecules necessary. Drug repositioning is an alternative that can be used to work around problems such as toxicity, cost and time in the development of new drugs. This study aims to evaluate the in vitro antifungal effect of tropicamide, molecule of anticholinergic action, against planktonic cells of Candida spp. and biofilm of C. albicans. Six strains of different Candida species were used to determine the minimum inhibitory concentration (MIC) of tropicamide and fluconazole according to CLSI document M27-A3 and one strain of C. albicans was used to evaluate the activity of tropicamide against biofilms. In concentrations of 64 μg/mL, the tropicamide exhibited 50% of inhibitory activity in planktonic cell and in concentrations of 128 μg/mL is able to inhibit the formation of C. albicans biofilm. Despite the inhibitory activity shown at the present study, the use of a larger number of strains, as well as in vivo cytotoxicity assays, is necessary to confirm the hypothesis that tropicamide can be used as an adjuvant agent in the treatment of infections by the Candida genus.